Carolyn was on the brink of death. Her recovery has doctors ‘shooting for a cure’
Carolyn McGrath, diagnosed with multiple myeloma over a decade ago, faced a grim prognosis after numerous treatments failed. A clinical trial involving a new immunotherapy drug, Elranatamab, led to significant improvements for many patients, including McGrath, who achieved remission. This breakthrough has made the drug accessible to more Australians, offering hope to those with limited options.
- ▪Carolyn McGrath was diagnosed with multiple myeloma in 2014 and underwent various treatments.
- ▪She participated in a clinical trial for a drug called Elranatamab, which resulted in her remission.
- ▪Over 60 percent of trial participants experienced cancer shrinkage, with 35 percent achieving undetectable levels of the disease.
Opening excerpt (first ~120 words) tap to expand
{"@context":"https://schema.org","@type":"NewsArticle","dateModified":"2026-05-22T09:00:00Z","datePublished":"2026-05-22T09:00:00Z","description":"Carolyn McGrath went through years of gruelling treatments, but the blood cancer always came back. Then a new drug trialled in Melbourne saved her life.","headline":"Carolyn was on the brink of death. Her recovery has doctors ‘shooting for a cure’","keywords":"Healthcare, Just in, For subscribers, Cancer","author":[{"@type":"Person","name":"Melissa Cunningham","jobTitle":"Health…
Excerpt limited to ~120 words for fair-use compliance. The full article is at The Sydney Morning Herald.